Genomic Profiling May Be Beneficial For Patients With Multiple Genomic Aberrations
A study was performed of more than 300 patients with diverse refractory cancers, including ovarian cancer, breast cancer, sarcoma, and renal cancer who had undergone next-generation sequencing of their tumor. “Matching Scores” were calculated for each patient based on the number of drug matches and genomic aberrations. It was found that high Matching Scores were independently associated with more frequent and longer remissions, as well as longer survival. Overall, the study offers a clinical proof of concept for the utility of comprehensive genomic profiling in assigning therapy to patients with refractory malignancies, especially in those patients with multiple genomic aberrations for whom combination therapies could be implemented.
Link to article in Cancer Research
*This study was selected by the American Society of Clinical Oncology (ASCO) for inclusion in Clinical Cancer Advances 2017, the Society’s annual review of progress against cancer and emerging trends in the field, and is featured as one of the year’s major achievements in clinical cancer research and care. Link